NVO news, real time NVO stock news, Novo-Nordisk A/S news today

News

NVO

52.40

-0.30%

-0.16

Novo Nordisk Soars as Wegovy Pill Changes the Game

TipRanks · 3h ago

Oral Wegovy Approval Is The Critical 2026 Lifeline Novo Nordisk Needs

Seeking Alpha · 22h ago

Should You Invest in Ozempic Maker Novo Nordisk in 2026?

The Motley Fool · 23h ago

Can Amgen Sustain Its Rally In 2026

Seeking Alpha · 23h ago

Bear of the Day: Novo Nordisk (NVO)

NASDAQ · 1d ago

What Does the Market Think About Novo Nordisk AS?

Benzinga · 1d ago

GLP-1 weight loss meds lead to changes in consumer food demand - study

Seeking Alpha · 1d ago

Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026

Barchart · 1d ago

Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?

The Motley Fool · 2d ago

GLP-1 Pills Gain Ground: Novo Nordisk Wins FDA Nod as Food Giants Tweak Strategy

TipRanks · 2d ago

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

Barchart · 2d ago

Novo Nordisk (NYSE:NVO): Reassessing Valuation After Recent Share Price Rebound

Simply Wall St · 2d ago

Novo Nordisk (NVO) Rises Higher Than Market: Key Facts

NASDAQ · 2d ago

Mixed options sentiment in Novo Nordisk with shares up 1.79%

TipRanks · 2d ago

Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval

Benzinga · 3d ago

Novo Nordisk: The Real Comeback Starts Now With The Wegovy Pill

Seeking Alpha · 3d ago

Novo Nordisk Expands Cardiovascular Ambitions With New Phase 3 Ziltivekimab Plaque Study

TipRanks · 3d ago

NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?

NASDAQ · 3d ago

Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)

Seeking Alpha · 3d ago

Unusually active option classes on open December 24th

TipRanks · 3d ago

Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.

About NVO

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.